Recently, Wondfo officially established subsidiaries in Russia and Philippines, marking another milestone in its global presence. In response to the Belt and Road Initiative, Wondfo will work closely with its partners to further deepen its presence in overseas markets, advancing biotechnology to benefit society.
On April 19, Wondfo celebrated the grand opening of its Russian subsidiary in Moscow. Since entering the Russian market in 2005, Wondfo products have been widely adopted by medical institutions across the country. The new subsidiary aims to integrate global innovation with localized service, contributing to the advancement of regional healthcare.
In his opening speech, Professor Wenmei Li, Founder of Wondfo, stated:" In the past 33 years, Wondfo has grown into a leading company in the POCT field, with products and services reaching over 150 countries and regions worldwide. We will continue to uphold the philosophy of building a 'community of shared interests, careers, and destiny,' and will work hand in hand with partners in Russia to achieve greater success and create greater value."
On April 23, Wondfo inaugurated its Philippine subsidiary in Taguig City, Manila. Having served the local market since 2012, Wondfo is now strengthening its commitment with a localized team and nationwide service network, aiming to further support local healthcare systems through reliable diagnostic solutions.
Wondfo's Chairwoman and Founder, Prof. Jihua Wang, stated that Wondfo has been actively strengthening its global presence, forging strong partnerships across regions, and remaining committed to creating unique opportunities to improve local health and well-being. "I believe this milestone will play a vital role in Wondfo's global journey. Let us work together to build a brighter future." she said.
Wondfo has maintained an active international presence since 2002. The opening of new subsidiaries reflects Wondfo's dedication to localization and long-term collaboration, reinforcing its efforts to strengthen healthcare infrastructure around the world.
Racing for Life, Wondfo will continue contributing to a healthier future — advancing biotechnology to benefit society.
The first developed technology platform with various application scenarios, including infectious disease, fertility, DOA, etc.
50+ kinds of reagents and five high-performance devices, focusing on detecting cardiovascular disease, inflammation, kidney injury, sex hormones, thyroid function, diabetes, tumor, and others.
Single-dose Chemiluminescense Immunoassay Platform
Wondfo optical blood coagulation analyzer is the first one in the world that can test PT, APTT, TT, FIB, and ACT simultaneously.
Our Blood Gas Analyzer BGA-102 can produce the result in 30s. Its advantages of portability, easy operation, durability, and high performance make it ideal for clinics, laboratories, and hospitals.
Ready-to-use lyophilized RT-PCR Reagent；
Wondfo PA-3600 IHC Staining System
The Wondfo Truth-H80E HPLC Hemoglobin Analyzer is a high-performance diagnostic device designed for rapid and precise measurement of glycosylated hemoglobin (HbA1c)—the gold standard for diabetes diagnosis.It support the standard mode and variant mode and provide the result within 60-90seconds.
Finecare™ Vitamin D, from complexity to simplicity
Building A World Free from Antibitoic Overuse
Advanced rapid diagnostic test with WHO prequalification for infectious disease
The Future Intelligent Medical Assistant to Healthcare
Fight against the pandemic through continuous innovation
